MannKind Corp (MNKD) FinancialsMNKDMannKind Corp

MannKind Corporation (MNKD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product sales, accounting for 65.4% of total sales, equivalent to $71.58M. Other significant revenue streams include Royalties and Services. Understanding this composition is critical for investors evaluating how MNKD navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, MannKind Corporation maintains a gross margin of 69.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -0.76%, while the net margin is -17.40%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MNKD converts its operational activities into shareholder value.

In the context of the broader market, MNKD competes directly with industry leaders such as MLTX and SPTX. With a market capitalization of $1.31B, it holds a significant position in the sector. When comparing efficiency, MNKD's gross margin of 69.00% stands against MLTX's N/A and SPTX's N/A. Such benchmarking helps identify whether MannKind Corporation is trading at a premium or discount relative to its financial performance.

MannKind reported a revenue of $109.4 million for Q2 2026, a 43% year-over-year increase, but also a net loss of $19 million, indicating mixed financial performance.